查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967595

PARP抑制劑生物標記市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、服務、應用、地區和競爭對手分類，2021-2031年

PARP Inhibitor Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Services, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 PARP 抑制劑生物標記市場預計將從 2025 年的 9.4214 億美元成長到 2031 年的 15.6361 億美元，複合年成長率達到 8.81%。

這些生物標記，包括BRCA突變和同源重組缺陷等特定分子指標，對於識別可能對聚（ADP-核糖）聚合酵素抑制劑療法產生反應的癌症患者至關重要。市場成長主要受精準醫療的進步以及越來越多的伴隨診斷獲準用於卵巢、乳癌和前列腺癌治療的監管核准的推動。這些惡性腫瘤發生率的上升進一步刺激了市場需求，因為有效的治療方案製定需要嚴格的診斷篩檢。例如，美國癌症協會預測，到2025年，美國將新增約313,780例前列腺癌病例，凸顯了準確評估生物標記以確保最佳治療管理的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 9.4214億美元
市場規模：2031年 1,563,610,000 美元
複合年成長率：2026-2031年 8.81%
成長最快的細分市場 成套工具
最大的市場 北美洲

儘管基因組分析發展勢頭強勁，但其高成本和複雜的報銷機制仍使其面臨許多挑戰。全球醫療體系間保險覆蓋政策的不一致和監管要求的差異，會嚴重限制患者獲得必要的伴隨診斷。這些經濟和行政障礙可能會阻礙生物標記檢測的臨床應用，並限制整個產業的成長，尤其是在價格敏感型市場。

市場促進因素

全球BRCA相關癌症發生率的不斷上升是生物標記市場發展的重要促進因素，也因此迫切需要可靠的診斷篩檢來識別適合PARP抑制劑治療的患者。隨著乳癌、卵巢和胰臟癌等惡性腫瘤發生率的持續成長，檢測種系和體細胞突變的臨床需求也日益增加。患者數量的成長與伴隨診斷的使用直接相關，因為識別BRCA1/2突變通常是標靶治療的監管前提條件。根據美國癌症協會2024年1月發布的《2024年癌症事實與數據》報告，預計美國女性將新增310,720例侵襲性乳癌病例，這意味著有大量患者需要進行基因組評估以製定有效的治療方案。

同時，臨床上對同源重組缺陷 (HRD) 分層和全面基因組分析的需求日益成長，正在加速市場發展。臨床醫師正從單一基因檢測轉向能夠捕捉更廣泛基因組不穩定性標記的廣譜檢測，這一趨勢得益於次世代定序(NGS) 技術的進步。精準腫瘤學領域診斷服務的快速發展也凸顯了這種向更全面的分子表徵發展的趨勢。例如，Myriad Genetics 在 2024 年 2 月報告稱，其全年檢測量同比成長 35%，凸顯了其診斷服務的廣泛應用。 Guardant Health 在 2024 年 2 月發布的報告進一步印證了這一強勁的需求，該公司在 2023 年為臨床客戶提供了 172,900 次檢測，同比成長 39%。

市場挑戰

全面的基因組分析成本高且報銷流程複雜，是全球PARP抑制劑生物標記市場成長的主要障礙。這些經濟障礙直接阻礙了伴隨診斷的廣泛應用，而伴隨診斷對於PARP抑制劑療法的處方至關重要。當保險拒付或患者需承擔高額自付費用時，這些關鍵檢測的臨床應用往往會停滯不前。因此，標靶治療的目標患者群無法充分識別，診斷開發商和製藥公司的獲利能力也受到極大限制。

此外，不同醫療體系間行政管理的不一致加劇了這項挑戰，阻礙了醫療產業在價格敏感地區充分發揮其潛力。這種情況造成了監管核准與病人實際就醫之間的差距，經濟摩擦也阻礙了醫療服務提供者進行必要的篩檢檢測。美國臨床腫瘤學會（ASCO）發布的一項2025年研究預測，晚期癌症的分子檢測率將維持在低於35%的水平，凸顯了由於就醫障礙導致的臨床指南與實際應用之間持續存在的差距。如果沒有統一的報銷機制，就很難將惡性腫瘤發生率的上升趨勢與永續的經濟成長聯繫起來。

市場趨勢

目前，液態生物檢體在非侵入性生物標記分析和縱向監測方面的應用顯著成長。臨床醫生正在擴大循環腫瘤DNA (ctDNA) 分析的應用範圍，以克服基於組織樣本的局限性，例如腫瘤異質性和重複切片檢查的侵入性。該技術能夠即時追蹤微量殘存疾病(MRD) 並早期發現抗藥性機制，這對於最佳化PARP抑制劑治療方案至關重要。這些以血液為基礎的診斷技術的快速普及也反映在產業績效指標中。根據Natera公司截至2025年2月的會計年度財務報告，該公司在2024年處理了約528,200例腫瘤檢測，年增54.9%，凸顯了市場對非侵入性分子監測日益成長的需求。

同時，人工智慧的整合正在革新基因組變異解讀，以應對大規模定序資料的複雜性。隨著診斷檢測範圍的擴大，涵蓋了全面的同源重組修復（HRR）基因，檢查室在對意義未明的變異（VUS）進行分類方面面臨著瓶頸。目前，人工智慧驅動的平台正被部署用於自動化變異註釋、提高分類準確率並加快關鍵治療決策的周轉時間。這種數位轉型使分散式檢查網路能夠有效率地擴展其精準醫療能力。例如，SOPHiA GENETICS在2025年3月報告稱，其數據驅動型醫療保健平台在2024年完成了創紀錄的35.2萬次分析。這反映出處理量年增11%，主要得益於先進分析工具的引進。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球PARP抑制劑生物標記市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（試劑盒、檢測方法）
    • 服務故障（BRCA1 和 BRCA2 檢測、HRD 檢測、HRR 檢測、其他）
    • 依應用領域（乳癌、卵巢癌等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美PARP抑制劑生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲PARP抑制劑生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區PARP抑制劑生物標記的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲PARP抑制劑生物標記的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲PARP抑制劑生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球PARP抑制劑生物標記市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Myriad Genetics, Inc.
  • Ambry Genetics
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • CENTOGENE NV
  • Amoy Diagnostics Co., Ltd.
  • Invitae Corporation
  • NeoGenomics Laboratories
  • QIAGEN NV
  • Agilent Technologies, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27188

The Global PARP Inhibitor Biomarkers Market is projected to expand from USD 942.14 Million in 2025 to USD 1563.61 Million by 2031, achieving a CAGR of 8.81%. These biomarkers, which encompass specific molecular indicators like BRCA mutations and homologous recombination deficiency status, are essential for identifying cancer patients who are likely to respond to poly (ADP-ribose) polymerase inhibitor treatments. The market's growth is primarily fueled by the advancing paradigm of precision medicine and the increasing number of regulatory approvals for companion diagnostics utilized in ovarian, breast, and prostate cancer care. This demand is further bolstered by the rising prevalence of these malignancies, which mandates rigorous diagnostic screening for effective treatment planning; for instance, the American Cancer Society expects approximately 313,780 new prostate cancer cases to be diagnosed in the United States in 2025, underscoring the significant need for accurate biomarker assessment to ensure optimal therapeutic management.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 942.14 Million
Market Size 2031USD 1563.61 Million
CAGR 2026-20318.81%
Fastest Growing SegmentKits
Largest MarketNorth America

Despite this robust growth trajectory, the market encounters significant challenges stemming from the high costs and complex reimbursement structures associated with comprehensive genomic profiling. Inconsistent insurance coverage policies and varied regulatory requirements across different global healthcare systems can severely restrict patient access to necessary companion diagnostics. These economic and administrative hurdles have the potential to hinder the broader clinical adoption of biomarker testing and constrain the overall expansion of the sector, particularly in markets that are highly sensitive to price.

Market Driver

The increasing global prevalence of BRCA-associated cancers serves as a fundamental driver for the biomarker market, creating an urgent need for robust diagnostic screening to identify patients eligible for PARP inhibitor therapy. As the incidence of malignancies such as breast, ovarian, and pancreatic cancers continues to rise, the clinical imperative to detect germline and somatic mutations has intensified. This growing patient volume correlates directly with the utilization of companion diagnostics, as the identification of BRCA1/2 mutations is frequently a regulatory prerequisite for prescribing targeted therapies. According to the American Cancer Society's "Cancer Facts & Figures 2024" report from January 2024, an estimated 310,720 new cases of invasive breast cancer were projected to be diagnosed in women in the United States, establishing a substantial baseline of patients requiring genomic evaluation for effective treatment planning.

Concurrently, the market is being accelerated by the growing clinical demand for Homologous Recombination Deficiency (HRD) stratification and comprehensive genomic profiling. Clinicians are increasingly transitioning from single-gene testing to broader panels that capture a wider array of genomic instability markers, a shift supported by advancements in Next-Generation Sequencing (NGS) technologies. This trend toward more extensive molecular characterization is evidenced by the rapid uptake of diagnostic services within the precision oncology sector. For instance, Myriad Genetics reported in February 2024 that its full-year testing volume grew by 35% year-over-year, highlighting the surge in diagnostic adoption. This strong demand is further illustrated by Guardant Health, which reported in February 2024 that it provided 172,900 tests to clinical customers in 2023, representing a 39% increase compared to the prior year.

Market Challenge

The substantial cost and reimbursement complexities linked to comprehensive genomic profiling present a formidable barrier to the growth of the Global PARP Inhibitor Biomarkers Market. These financial obstacles directly impede the widespread adoption of companion diagnostics, which are strictly required for prescribing PARP inhibitor therapies. When insurance policies deny coverage or impose significant out-of-pocket expenses, the clinical uptake of these critical tests often stagnates. Consequently, the pool of patients eligible for targeted therapies remains under-identified, which effectively limits the revenue potential for both diagnostic developers and pharmaceutical companies.

Furthermore, administrative inconsistencies across various healthcare systems exacerbate this challenge, preventing the sector from achieving its full potential in price-sensitive regions. This situation creates a disconnect between regulatory approval and actual patient access, as economic friction discourages healthcare providers from ordering necessary screens. According to a 2025 study highlighted by the American Society of Clinical Oncology, the molecular testing rate for advanced cancers remained at a suboptimal 35%, underscoring the persistent gap between clinical guidelines and actual utilization due to access barriers. Without consistent reimbursement pathways, the market struggles to convert the rising prevalence of malignancies into sustained economic expansion.

Market Trends

The market is currently experiencing a significant shift toward the use of liquid biopsy for non-invasive biomarker profiling and longitudinal monitoring. Clinicians are increasingly adopting circulating tumor DNA (ctDNA) analysis to address the limitations of tissue-based sampling, such as tumor heterogeneity and the invasive nature of repeat biopsies. This method facilitates real-time tracking of Minimal Residual Disease (MRD) and the early detection of resistance mechanisms, both of which are critical for optimizing PARP inhibitor regimens. The rapid adoption of these blood-based diagnostics is reflected in industrial performance metrics; according to Natera's February 2025 financial results, the company processed approximately 528,200 oncology tests in 2024, a substantial 54.9% increase compared to the prior year, underscoring the surging demand for non-invasive molecular monitoring.

Simultaneously, the integration of artificial intelligence is revolutionizing genomic variant interpretation to manage the complexity of large-scale sequencing data. As diagnostic panels expand to include comprehensive homologous recombination repair (HRR) genes, laboratories face a bottleneck in classifying Variants of Uncertain Significance (VUS). AI-driven platforms are now being deployed to automate variant curation, improve classification accuracy, and accelerate turnaround times for critical treatment decisions. This digital transformation enables decentralized testing networks to scale their precision medicine capabilities efficiently. As evidence of this trend, SOPHiA GENETICS reported in March 2025 that it performed a record 352,000 analyses globally on its data-driven medicine platform in 2024, reflecting an 11% year-over-year volume growth driven by the adoption of these advanced analytical tools.

Key Market Players

  • Myriad Genetics, Inc.
  • Ambry Genetics
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • CENTOGENE N.V.
  • Amoy Diagnostics Co., Ltd.
  • Invitae Corporation
  • NeoGenomics Laboratories
  • QIAGEN N.V.
  • Agilent Technologies, Inc.

Report Scope

In this report, the Global PARP Inhibitor Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

PARP Inhibitor Biomarkers Market, By Product

  • Kits
  • Assays

PARP Inhibitor Biomarkers Market, By Services

  • BRCA 1 & 2 Testing
  • HRD Testing
  • HRR Testing
  • Others

PARP Inhibitor Biomarkers Market, By Application

  • Breast Cancer
  • Ovarian Cancer
  • Others

PARP Inhibitor Biomarkers Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global PARP Inhibitor Biomarkers Market.

Available Customizations:

Global PARP Inhibitor Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global PARP Inhibitor Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Kits, Assays)
    • 5.2.2. By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others)
    • 5.2.3. By Application (Breast Cancer, Ovarian Cancer, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America PARP Inhibitor Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Services
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States PARP Inhibitor Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Services
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada PARP Inhibitor Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Services
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico PARP Inhibitor Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Services
        • 6.3.3.2.3. By Application

7. Europe PARP Inhibitor Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Services
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany PARP Inhibitor Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Services
        • 7.3.1.2.3. By Application
    • 7.3.2. France PARP Inhibitor Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Services
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom PARP Inhibitor Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Services
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy PARP Inhibitor Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Services
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain PARP Inhibitor Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Services
        • 7.3.5.2.3. By Application

8. Asia Pacific PARP Inhibitor Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Services
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China PARP Inhibitor Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Services
        • 8.3.1.2.3. By Application
    • 8.3.2. India PARP Inhibitor Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Services
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan PARP Inhibitor Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Services
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea PARP Inhibitor Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Services
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia PARP Inhibitor Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Services
        • 8.3.5.2.3. By Application

9. Middle East & Africa PARP Inhibitor Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Services
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia PARP Inhibitor Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Services
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE PARP Inhibitor Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Services
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa PARP Inhibitor Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Services
        • 9.3.3.2.3. By Application

10. South America PARP Inhibitor Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Services
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil PARP Inhibitor Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Services
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia PARP Inhibitor Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Services
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina PARP Inhibitor Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Services
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global PARP Inhibitor Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Myriad Genetics, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Ambry Genetics
  • 15.3. Thermo Fisher Scientific, Inc.
  • 15.4. Illumina, Inc.
  • 15.5. CENTOGENE N.V.
  • 15.6. Amoy Diagnostics Co., Ltd.
  • 15.7. Invitae Corporation
  • 15.8. NeoGenomics Laboratories
  • 15.9. QIAGEN N.V.
  • 15.10. Agilent Technologies, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer